Chacko Jacob 4

4 · Oric Pharmaceuticals, Inc. · Filed Dec 17, 2024

Form 4

Period: 2024-12-15

DirectorPRESIDENT AND CEO

Transactions

Exercise/Conversion
Common Stock
2024-12-15+67,000→ 803,308 total
Sale
Common Stock
2024-12-16$8.28/sh−24,660$204,214→ 778,648 total
Exercise/Conversion
Restricted Stock Unit
2024-12-15−22,000→ 22,000 total
→ Common Stock (22,000 underlying)
Exercise/Conversion
Restricted Stock Unit
2024-12-15−28,333→ 56,667 total
→ Common Stock (28,333 underlying)
Exercise/Conversion
Restricted Stock Unit
2024-12-15−16,667→ 0 total
→ Common Stock (16,667 underlying)

Footnotes (7)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
[F2]Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
[F3]Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
[F4]Represents the weighted average share price of an aggregate total of 24,660 shares sold in the price range of $8.27 to $8.39 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F5]1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024.
[F6]1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
[F7]1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

Documents

1 file